A Phase 1 Dose-Escalation and Expansion Study of CUE-101, Given As Monotherapy and in Combination with Pembrolizumab, in Patients with Recurrent/metastatic HPV16+ Head and Neck Squamous Cell Cancer (R/M HNSCC).
JOURNAL OF CLINICAL ONCOLOGY(2024)
AI Read Science
Must-Reading Tree
Example

Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined